Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7787142 | 0.82 | STS (0.59) | STSTGFBR1GPR119CYP3A4CACNA1B | |
| SCHEMBL2191964 | 0.79 | CACNA1B (0.62) | STSTGFBR1GPR119CYP3A4CACNA1B | |
| SCHEMBL21722811 | 0.74 | STS (0.54) | STSTGFBR1GPR119DPP4SCN9A | |
| SCHEMBL17942390 | 0.74 | CYP3A4 (0.54) | STSTGFBR1GPR119CYP3A4CACNA1B | |
| SCHEMBL17948997 | 0.74 | STS (0.44) | STSTGFBR1GPR119MEN1KMT2A | |
| SCHEMBL17948973 | 0.73 | STS (0.55) | STSTGFBR1GPR119 | |
| SCHEMBL29530166 | 0.72 | GPR119 (0.52) | STSTGFBR1GPR119CYP3A4CACNA1B | |
| SCHEMBL17948857 | 0.72 | GPR119 (0.52) | STSTGFBR1GPR119CYP3A4CACNA1B | |
| SCHEMBL18025954 | 0.72 | PIK3CD (0.44) | STSGPR119KMT2A | |
| SCHEMBL13932867 | 0.72 | STS (0.74) | STSTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234604-A1 | Process for Making Substituted Aryl Sulfone Intermediates | LINGHU XIN | 2010-09-16 | — | — | US | disclosed |
| US-20100234603-A1 | Process for Making Substituted Aryl Sulfone Intermediates | LINGHU XIN | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234604-A1 | Process for Making Substituted Aryl Sulfone Intermediates | SULT1A1, SULT1E1, STS | STS 3/4885TGFBR1 4018/4885GPR119 4733/4885 |
| US-20100234603-A1 | Process for Making Substituted Aryl Sulfone Intermediates | SULT1A1, SULT1E1, STS | STS 3/4885TGFBR1 4018/4885GPR119 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.